News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
363,983 Results
Type
Article (24159)
Company Profile (31)
Press Release (339793)
Section
Business (121717)
Career Advice (1439)
Deals (17674)
Drug Delivery (57)
Drug Development (43482)
Employer Resources (97)
FDA (8828)
Job Trends (8642)
News (194283)
Policy (17497)
Tag
Academia (1472)
Alliances (33426)
Alzheimer's disease (732)
Approvals (8807)
Artificial intelligence (91)
Bankruptcy (155)
Best Places to Work (7116)
Breast cancer (80)
Cancer (716)
Cardiovascular disease (59)
Career advice (1221)
Cell therapy (148)
Clinical research (34383)
Collaboration (282)
COVID-19 (1481)
Data (773)
Diabetes (106)
Diagnostics (3304)
Earnings (54058)
Employer resources (85)
Events (53601)
Executive appointments (174)
FDA (9148)
Funding (197)
Gene therapy (116)
GLP-1 (348)
Government (2331)
Healthcare (10276)
Infectious disease (1524)
Inflammatory bowel disease (72)
Interviews (265)
IPO (8330)
Job creations (1825)
Job search strategy (1020)
Layoffs (225)
Legal (4463)
Lung cancer (125)
Manufacturing (112)
Medical device (6591)
Medtech (6595)
Mergers & acquisitions (9426)
Metabolic disorders (260)
Neuroscience (896)
NextGen Class of 2024 (3466)
Non-profit (2695)
Northern California (820)
Obesity (141)
Opinion (150)
Patents (64)
People (28292)
Phase I (10248)
Phase II (14701)
Phase III (12322)
Pipeline (394)
Podcasts (56)
Policy (52)
Postmarket research (1685)
Preclinical (4463)
Radiopharmaceuticals (144)
Rare diseases (130)
Real estate (2620)
Regulatory (11439)
Research institute (1352)
Resumes & cover letters (221)
Southern California (719)
Startups (1591)
United States (7618)
Vaccines (367)
Weight loss (104)
Date
Today (74)
Last 7 days (484)
Last 30 days (2381)
Last 365 days (20795)
2024 (19115)
2023 (22752)
2022 (29304)
2021 (31035)
2020 (30172)
2019 (25779)
2018 (19049)
2017 (18060)
2016 (17472)
2015 (19906)
2014 (16595)
2013 (14521)
2012 (14385)
2011 (13849)
2010 (13074)
Location
Africa (559)
Arizona (62)
Asia (21196)
Australia (3561)
California (1794)
Canada (749)
China (149)
Colorado (96)
Connecticut (101)
Europe (50278)
Florida (313)
Georgia (76)
Illinois (174)
Indiana (126)
Japan (51)
Kansas (49)
Maryland (295)
Massachusetts (1452)
Michigan (85)
Minnesota (118)
New Jersey (629)
New York (614)
North Carolina (432)
Northern California (820)
Ohio (74)
Pennsylvania (476)
South America (766)
Southern California (719)
Texas (248)
Utah (62)
Washington State (214)
363,983 Results for "merck sharp and dohme".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Clinical research
Merck’s Subcutaneous Keytruda Meets Expectations in Phase III
Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster goes off patent in 2028.
November 19, 2024
·
2 min read
·
Annalee Armstrong
Vaccines
CDC Panel Recommends Merck and Pfizer Pneumococcal Vaccines for Adults Aged 50–64
The CDC’s Advisory Committee on Immunization Practices on Wednesday backed the use of Merck’s Capvaxive and Pfizer’s Prevnar 20 in adults between 50-64 years of age, opening a bigger market for the respective companies.
October 24, 2024
·
2 min read
·
Tristan Manalac
Collaboration
Merck Hops Onto PD-1/VEGF Train, Committing up to $3B Plus in LaNova Deal
Despite recent enthusiasm around the PD-1/VEGF space, BMO Capital Markets analyst Evan Seigerman noted that Merck’s pact with LaNova Medicines is more “conservativism” on the pharma’s part than confirmatory of recent data in the drug class.
November 14, 2024
·
2 min read
·
Tristan Manalac
Earnings
Merck Lowers Full-Year Sales Guidance Despite Strong Overall Q3 Results
Offsetting Merck’s growth in the third quarter were disappointing revenues from its HPV vaccine Gardasil and type 2 diabetes pill Januvia, with the company on Thursday narrowing its 2024 sales and adjusted profit outlooks.
October 31, 2024
·
2 min read
·
Tristan Manalac
Cancer
Merck’s Keytruda Combo Fails in Phase III Colorectal Cancer Study
Merck follows in the footsteps of Bristol Myers Squibb, which in December 2023 also failed to secure a late-stage victory for its combo regimen of a PD-1 blocker and an anti-LAG-3 antibody.
September 25, 2024
·
2 min read
·
Tristan Manalac
RSV
Merck, Pfizer Tout Promising Respective Data in RSV With High Rates of Prevention
Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory syncytial virus-associated infections in infants, while Pfizer’s RSV vaccine Abrysvo showed 90% effectiveness at preventing the most severe RSV cases in adults 60 years and older.
October 18, 2024
·
2 min read
·
Tristan Manalac
BioMidwest
PharmaLink Announces Execution of Returns Processing Service Agreement With Merck
PharmaLink, Inc., an Industry-leading pharmaceutical reverse distributor, announced a new contract relationship with biopharmaceutical manufacturer Merck Sharp & Dohme LLC.
June 13, 2023
·
2 min read
Pharm Country
Sharps Technology Receives $30 Million Purchase Order for Prefillable Copolymer Syringes to be Manufactured at SC Facility
Sharps Technology, Inc. received a signed $30 million purchase order from Nephron Pharmaceuticals, representing their first 12 months of syringe purchase commitments.
June 13, 2024
·
6 min read
Drug Development
Keytruda Redeems Itself in Head and Neck Cancer as Merck Lands Potential $1.9B I&I Collab
On the heels of Keytruda’s success in a Phase III perioperative trial for a disease where it had previously failed to improve event-free survival, Merck touts an I&I deal with UK biotech Mestag.
October 8, 2024
·
2 min read
·
Kate Goodwin
Infectious Disease
CDC Backs Merck’s Capvaxive, Tees Up Pneumococcal Competition With Pfizer
In a potential challenge to Pfizer’s Prevnar 20, Merck’s Capvaxive has been recommended by the Centers for Disease Control and Protection for use in preventing invasive pneumococcal disease in adults.
July 1, 2024
·
2 min read
·
Tristan Manalac
1 of 36,399
Next
